China Dips Its Toes in Disruptive IVD Tech
Executive Summary
The number of Chinese IVD companies exhibiting at the 2015 American Association for Clinical Chemistry Annual Meeting (AACC) & Clinical Lab Expo (CLE) was slightly down from last year, but the breadth of diagnostic products and innovations from China appears to be on the up. Hrishi Poola and Jon Chen discuss the moves China is making to become a generator of disruptive technologies and reports on the new products and the players emerging from this market
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.